Overview

* Pliant Q3 net loss narrows to $26.3 mln, driven by BEACON-IPF discontinuation

* Company completed voluntary prepayment of Oxford Finance loan

Outlook

* BEACON-IPF close out activities to be completed in Q4 2025

Result Drivers

* R&D EXPENSES - Decrease primarily due to discontinuation of BEACON-IPF trial

* ADMINISTRATIVE COSTS - Decline due to strategic workforce restructuring

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$26.30

Income mln

Q3 -$28.27

Operatin mln

g

Expenses

Q3 -$28.27

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Pliant Therapeutics Inc ( PLRX ) is $3.00, about 45.3% above its November 5 closing price of $1.64

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)